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Background: microRNAs (miRNAs) have been reported to modulate macrophage colony-stimulating factor (M-CSF)
and macrophages. The aim of this study was to find whether miR-26a can suppress M-CSF expression and the
recruitment of macrophages.
Methods: Hepatocellular carcinoma (HCC) cell lines with decreased or increased expression of miR-26a were
established in a previous study. M-CSF expression by tumor cells was measured by enzyme-linked immunosorbent
assay, and cell migration assays were used to explore the effect of HCC cell lines on macrophage recruitment in vitro.
Real-time PCR measured a panel of mRNAs expressed by macrophages. Xenograft models were used to observe tumor
growth. Immunohistochemistry was conducted to study the relation between miR-26a expression and M-CSF
expression and macrophage recruitment in patients with HCC.
Results: Ectopic expression of miR-26a reduced expression of M-CSF. The conditioned medium (CM) from HepG2 cells
that overexpressed miR-26a reduced the migration ability of THP-1 cells stimulated by phorbol myristate acetate (PMA)
increased expression of interleukin (IL)-12b or IL-23 mRNA and decreased expression of chemokine (C-C motif) ligand
(CCL)22, CCL17, and IL-10 mRNA, in comparison to the medium from the parental HepG2 cells. These effects could be
interrupted by the PI3K/Akt pathway inhibitor LY294002. Ectopic expression of miR-26a in HCC cells suppressed tumor
growth, M-CSF expression, and infiltration of macrophages in tumors. Similar results were also found when using
HCCLM3 cells. Furthermore, the expression of miR-26a was inversely correlated with M-CSF expression and macrophage
infiltration in tumor tissues from patients with HCC.
Conclusions: miR-26a expression reduced M-CSF expression and recruitment of macrophages in HCC.
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Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and third leading cause of cancer-related death
worldwide [1]. Treatment of HCC has changed greatly in
recent years, but hepatic resection and transplantation
are still considered the main curative therapy, and a high
postoperative recurrence rate is a major impediment to
prolonging patient survival [2].
Crosstalk between tumor cells and their microenvir-
onment underlies the pathogenesis of HCC [3]. Trans-
plantation of normal hepatocytes into a neoplastic-prone
liver microenvironment delays the growth of hepatic nod-
ules and the emergence of HCC [4]. A unique immune/
inflammation response signature is associated with HCC
intrahepatic metastasis, and inflammatory cytokines
can predict poor survival of patients with HCC [5, 6].
These findings suggest that the immune/inflammation
microenvironment may foster the development of HCC.
Tumor-associated macrophages (TAMs) are key com-
ponents of the cancer microenvironment [7, 8]. TAMs
originate from circulating monocyte precursors that are
recruited to the tumor by tumor-derived signals, including
chemokine (C-C motif) ligand 2 (CCL2) and macrophage
colony-stimulating factor (M-CSF). In response to distinct
microenvironment signals, macrophages can exert ei-
ther anti- or pro-tumor activities [9], classified as M1
(or classical) or M2 (or alternatively activated), respectively
[10, 11]. In HCC, most macrophages in the peritumor
region exhibit an M2 phenotype, which is probably de-
termined by the tumor cell [12, 13]. These macrophages
facilitate tumor growth, metastasis, and angiogenesis and
are associated with poor patient survival [13–16]. In many
types of tumors, M-CSF is an essential regulator or re-
cruiter of macrophages and is mainly produced by tumor
cells [17, 18]. After binding to colony-stimulating factor 1
receptor (CSF-1R) on macrophages, M-CSF can activate
macrophages, promoting secretion of growth factors that
are essential for the pre-metastatic niche and tumor growth
or metastasis [19–21]. Some studies have also found high
expression of M-CSF and its receptor in peritumoral liver
tissue, which is associated with poor survival of patients
with HCC after curative resection [6, 22].
microRNAs (miRNAs) are a class of 22-nucleotide non-
coding RNAs. The aberrant expression of specific miRNAs
is directly involved in tumorigenesis, including growth,
apoptosis, angiogenesis, and metastasis [23–27] and
affects the biology of cellular components belonging
to the tumor microenvironment, including endothelial
cells, pericytes, fibroblasts, and immune cells [28–31].
In HCC, miRNAs have been reported to regulate the
biology of endothelial cells and Treg cells [32, 33]. It
has also been reported that miR-214 modulates macro-
phage polarization in HCC [34]. However, no study has
addressed whether miRNAs regulate M-CSF expressionin tumor cells and the recruitment of macrophages in
HCC.
Deregulation of miR-26a may function as either a tumor
suppressor or promoter. miR-26a is down-regulated in
breast cancer, anaplastic carcinomas, and oral squamous
cell carcinoma [35–38] but up-regulated in cholangiocar-
cinoma and glioma [39–41]. In HCC, a reduced level of
miR-26a is associated with poor overall survival of patients
with HCC [42]. Patients with hepatitis B virus-related
HCC had a lower level of miR-26a in blood compared
with patients with chronic hepatitis B [43]. In addition,
miR-26a can inhibit cancer cell proliferation and protect
against disease progression without toxicity in an HCC
mouse model [44–46]. The underlying mechanisms
might be that miR-26a can inhibit tumor growth, metasta-
sis, and angiogenesis in HCC [27, 44, 47, 48]. However, no
study has addressed the role of miR-26a in TAMs.
In the present study, we investigated whether miR-26a
regulates recruitment and function of macrophages in
HCC and the underlying mechanisms of miR-26a.
Results
miR-26a suppressed the attraction of macrophages by
inhibiting M-CSF secretion
In a previous study [27], we found miR-26a suppressed
the activation of the PI3K/Akt signal pathway. Because
M-CSF is an important cytokine for macrophage recruit-
ment and can be modulated by the PI3K/Akt signal path-
way [49], we investigated whether miR-26a can regulate the
expression of M-CSF and the attraction of macrophages in
HCC.
We first collected conditioned medium (CM) from HCC
cell lines established in our previous study that stably
expressed miR-26a at different levels. These cells lines in-
cluded HepG2-wt (wild type of HepG2), HepG2-control
(HepG2 transfected with the negative control of precursor
miRNA), and HepG2-miR-26a (HepG2 transfected with
pre-miR-26a) and HCCLM3-wt (wild type of HCCLM3),
HCCLM3-control (HCCLM3 transfected with the nega-
tive control of anti-miRNA-locked nucleic acids [LNAs]),
and HCCLM3-anti-miR-26a (HCCLM3 transfected with
anti-miRNA-LNAs against miR-26a). Then, the protein
level of M-CSF was detected by enzyme-linked immuno-
sorbent assay (ELISA). We found that secretion of M-CSF
was significantly decreased in the CM of HepG2-miR-
26a but significantly increased in HCCLM3-anti-miR-
26a (Fig. 1a).
To explore whether miR-26a affects motility of macro-
phages, a migration assay was conducted using THP-1
cells stimulated by PMA. We found that the migration
of THP-1 cells was inhibited by the CM of HepG2-miR-
26a cells and induced by the CM from HCCLM3-anti-miR-
26a cells (Fig. 1b) in comparison to CM from the control
cells.
Fig. 1 miR-26a suppressed the motility of macrophages by inhibiting M-CSF secretion. a After the modifications of miR-26a in HCC cell lines, the
level of M-CSF in the CM of HCC cells was detected by ELISA. b THP-1 cells stimulated by PMA were treated with CM from all HCC cells, and their
migration ability was assessed. c, d THP-1 cells stimulated by PMA were treated with CM from HCC cells with addition of M-CSF neutralizing
antibody or control IgG, and their migration was assessed
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motility of macrophages was mediated by M-CSF, we
added M-CSF-neutralizing antibody and human M-CSF
protein into the CM we collected. The results showed
that THP-1 cell migration was suppressed by the CM of
HepG2 cells treated with M-CSF-neutralizing antibody
and induced by the CM of HepG2 cells treated with the
extrinsic M-CSF protein. Furthermore, the difference in
migration ability between HepG2-control and HepG2-miR-26a cells was eliminated (Fig. 1c). Similar results
were also found in HCCLM3 cells (Fig. 1d).
miR-26a inhibited the expression of M-CSF by regulating
the PI3K/Akt pathway
To explore whether miR-26a affects M-CSF expression
through the PI3K/Akt pathway, the PI3K/Akt pathway
inhibitor LY294002 was used. The results showed that
expression of M-CSF in HepG2 cells was inhibited by
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the total Akt expression was not affected (Fig. 2d). Migra-
tion of THP-1 cells was inhibited (Fig. 2b, c). LY294002
treatment also eliminated the difference in M-CSF secre-
tion and migration of THP-1 cells among HepG2-wt,
HepG2-control, and HepG2-miR-26a cells. Similar results
were also found in HCCLM3 cells (Fig. 2e–h).
miR-26a affected polarization of macrophages
Because M1 macrophages produce higher levels of inter-
leukin (IL)-12b and IL-23 and lower levels of IL-10,
CCL17, and CCL22 compared with M2 macrophagesFig. 2 The inhibiting effect of miR-26a on macrophages mainly through re
cells, and the CM was collected. a, f The expression levels of M-CSF in th
of CM on migration of THP-1 cells stimulated by PMA was assessed. d, e
Western blot[50, 51], we examined mRNA expression of these cyto-
kines in the THP-1 cells stimulated by PMA and treated
with the CM of HCC cells to study whether miR-26a af-
fects polarization of macrophages. The results showed
that the THP-1 cells treated with CM of HepG2-miR-26a
cells expressed more IL-12b and IL-23 mRNA and less
CCL22, CCL17, and IL-10 mRNA in comparison with
THP-1 cells treated with the CM of HepG2-control cells
(Fig. 3a). In contrast, the THP-1 cells treated with CM of
HCCLM3-anti-miR-26a cells had lower IL-12b and IL-23
mRNA expression but higher CCL22, CCL17, and IL-10
mRNA expression.gulation of the PI3K/Akt pathway. LY294002 was used to treat HCC
e CM of all HCC cells were assessed by ELISA. b, c, g, h The effect
The expression of Akt and p-Akt in HCC cells were examined by
Fig. 3 The regulatory effect of miR-26a on a panel of mRNA expressed by macrophages. THP-1 cells stimulated by PMA were treated with CM
from HCC cells. The mRNA expression of IL-12b, IL-23, IL-10, CCL17, and CCL22 in the THP-1 cells treated with CM from HepG2-miR-26a and
HepG2-control cells (a) or HCCLM3-anti-miR-26a and HCCLM3-control cells (b) were detected by RT-PCR
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macrophages in HCC xenograft models
To evaluate the role of miR-26a on recruitment of mac-
rophages, we established HepG2 and HCCLM3 xenograft
models. Similar to our previous findings [27], HepG2-
miR-26a tumors had a decreased tumor volume, while
HCCLM3-anti-miR-26a tumors had an increased volume
compared with their parental cell lines, respectively
(Fig. 4a, b). Further investigation of the M-CSF expression
and infiltrating macrophages revealed that HepG2-miR-
26a tumors had lower M-CSF expression and a decreasednumber of infiltrating macrophages compared with
HepG2-control tumors (Fig. 4c, d). HCCLM3-anti-miR-
26a tumors had higher M-CSF expression and fewer
macrophages compared with HCCLM3-control tumors
(Fig. 4e, f ).
miR-26a expression was inversely correlated with M-CSF
expression and infiltrating macrophages in tumors from
patients with HCC
To examine whether miR-26a expression was correlated
with M-CSF expression and the density of macrophages,
Fig 4 (See legend on next page.)
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Fig 4 The role of miR-26a on M-CSF expression and recruitment of macrophages in vivo. HCC cells were injected into the right flanks of nude
mice. a, b The tumor growth curves of subcutaneous tumors were assessed. c, d The M-CSF expression and CD68 expression in the tumors of
HepG2 cells were assessed by immunohistochemistry. e, f The M-CSF expression and CD68 expression in the tumors of HCCLM3 cells were
assessed by immunohistochemistry. Representative images are shown (×200)
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and CD68 expression in 80 patients with HCC. miR-26a
expression data were obtained in our previous study [42].
The representative images of M-CSF and CD68 immuno-
staining are shown in Fig. 5a. The statistical results for
M-CSF expression showed that miR-26a expression was
inversely correlated with the M-CSF expression (Fig. 5b).
After dividing the patients into two equal groups, using
the median value of miR-26a expression as the cutoff
point, we found that patients with higher miR-26a ex-
pression had lower M-CSF expression compared with
patients with lower miR-26a expression (Fig. 5c). We
found similar results in the analysis of the relation be-
tween miR-26a and CD68 expression (Fig. 5d, e).
Discussion
miR-26a has been reported to be able to reduce prolifera-
tion, metastasis, and angiogenesis in HCC [27, 44, 47, 48].
We further demonstrated that miR-26a can regulate the
recruitment of macrophages. Some studies have reported
miRNAs associated with macrophage infiltration, apop-
tosis, and phenotype. For example, let-7d suppresses
macrophage infiltration by targeting COL3A1 and CCL7
[52], miR-142-5p can regulate apoptosis of macrophages
by targeting TGF-β2 [53], and miR-155 can modulate
macrophage polarization by targeting C/EBP-β [54]. Here,
we first demonstrated that miR-26a can suppress macro-
phage recruitment by regulating M-CSF expression in
HCC.
In our previous study, we found that miR-26a expression
was lower in HCC tumor samples than in paired noncan-
cerous liver tissue, and patients with lower miR-26a
expression had shorter overall survival compared with
patients with higher miR-26a expression [42]. The under-
lying mechanism related to miR-26a may be suppression
of HCC cell proliferation and metastasis by regulation of
the IL-6-stat3 signaling pathway and inhibition of angio-
genesis in HCC by down-regulating Akt/VEGF signaling
[27, 47, 48]. In addition, Kota et al. [44] reported that
miR-26a can inhibit cancer cell proliferation in an HCC
mouse model by targeting cyclin D2 and E2. However,
the underlying mechanisms for how miR-26a affects the
survival of patients with HCC are still not fully understood.
The present study was designed to show a new role of
miR-26a in the recruitment of macrophages in HCC.
M-CSF is one of the major cytokines controlling the
proliferation, differentiation, and functional regulation of
macrophage [55]. The expression level of M-CSF hasbeen found to be associated with higher histological tumor
grading, more frequent metastases, and poor prognosis
in many cancer types, including papillary renal cell car-
cinoma, serous and mucinous ovarian epithelial tumors,
endometrioid carcinomas, breast cancer, and especially
HCC [51, 56–59]. Our previous study showed that high
expression of M-CSF in peritumoral liver tissue is asso-
ciated with poor survival after curative resection of HCC
[6, 22]. Various miRNAs have been reported to be involved
in the regulation of M-CSF expression. Mandal et al. [49]
found miR-21a can induce M-CSF expression by regulating
the PI3K/Akt signal pathway. Cimino et al. [60] reported
M-CSF is a direct target of miR-148b. Wang et al. [61]
identified M-CSF as a target gene of miR-214, and Zhang
et al. [62] reported M-CSF as a target of miR-128. The
present study found miR-26a regulates M-CSF expression
and recruitment of macrophages. In addition, M-CSF also
plays an important role in the polarization of macrophages.
It can stimulate macrophages and induce them to exhibit
an anti-inflammatory M2-type of activation, which pro-
duces higher IL-12/23 but lower CCL17, CCL22, and
IL-10 [50, 51, 63, 64]. The present study also found
miR-26a can induce a pro-inflammatory M1-type of
activation for macrophages and may affect the overall
survival of patients with HCC partly through reducing
macrophage recruitment and down-regulating M-CSF
expression.
This study has some potential limitations. We found
miR-26a can inhibit macrophage recruitment by down-
regulating M-CSF expression, but recruitment might be
influenced by many factors. Our preliminary study showed
miR-26a expression did not affect expression of CCL2 and
GM-CSF (data not shown), which are two major cytokines
regulating recruitment of macrophages [51, 65].
M-CSF inhibitor has been reported to impede macro-
phage recruitment in malignancy [66]. For HCC, zoledro-
nic acid, a bisphosphonate with a macrophage-modulating
effect, can inhibit growth of HCC cells and delay disease
progression of bone metastases [67, 68]. Our previous
study reported that depletion of macrophages using zo-
ledronic acid can enhance the effect of sorafenib in HCC
as well [69]. With all data considered together, M-CSF
and macrophage might be potential therapeutic targets for
HCC. Our data provide evidence that miR-26a may sup-
press the recruitment of macrophages by down-regulating
M-CSF expression. The data also suggest that miR-26a
may be a marker for the grade of malignancy in HCC as
well as a potential therapeutic target in patients with HCC.
Fig. 5 The relationship between miR-26a and the expression M-CSF and the density of macrophages in HCC tissue. a The HCC tissue microarrays
were used to analyze M-CSF expression and density of macrophages through immunohistochemistry. Representative images are shown (×200).
b, c The relationship between M-CSF expression and miR-26a expression was analyzed. d, e The relationship between the density of macrophages
and miR-26a expression was analyzed. IOD integrated optical density
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Cell lines
The HCC cells which were altered expression levels of miR-
26a by using recombinant lentivirus vector (Genechem,
Shanghai, China) were established in our previous study.
Human monocyte cell line THP-1 were obtained from
Shanghai Institute of Cell Biology (Shanghai, China). The
HCC cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen, Carlsbad, CA) containing
10 % fetal bovine serum (FBS), and THP-1 cells were
cultured in RPMI 1640 (Invitrogen, Carlsbad, CA) sup-
plemented with 10 % FBS. All cells were maintained in
a humidified incubator at 37 °C with an atmosphere of
5 % CO2.
Collection of the CM
HCC cells were treated with LY294002 (20 μM, Beyotime,
Jiangsu, China) or vehicle for 12 h, then incubated in
DMEM with 0.1 % BSA for 24 h. The CM was centrifuged
for 20 min at 3000 rpm, and the resultant pellet was stored
at −80 °C. In the M-CSF blocking assay experiments,
neutralizing antibody against M-CSF (R&D Systems,
Minneapolis, MN) and control IgG were added to CM
30 min before further experiments.
Quantification of M-CSF in the CM
ELISA (R&D Systems) was used to measure M-CSF con-
centrations in the CM. The total protein concentration
was measured by bicinchoninic acid (BCA) assay, and the
M-CSF concentration was normalized according to the
total cellular protein.
Cell migration assay
Chambers (Corning, Tewksbury, MA) with 8.0-μm poly-
carbonate filter inserted in 24-well plates were used in
the quantitative cell migration assays as described before
[27]. THP-1 cells stimulated by PMA (1 × 105 cells/well)
were added in the upper chamber, and the lower cham-
ber was filled with the previously collected CM. The 24-
well plates filled with cells were placed in a thermostatic
incubator at 37 °C for 16 h. Thereafter, the migrated
cells were fixed with methanol, stained with crystal violet,
and photographed under an inverted microscope. The
areas of stained cells from three random fields at × 200
magnification were assessed by using Image-Pro Plus
software (Media Cybernetics Inc, Bethesda, MD).
Western blot assay
As described in our previous study [27], cells were lysed
in buffer (150 mM NaCl, 50-mM Tris-HCl, pH 8.0,
0.1 % SDS, 1 % Triton X-100) containing protease and
phosphatase inhibitors. Fifty micrograms of whole cell
extracts were subjected to SDS-PAGE gel and transferred
to nitrocellulose membranes. The membranes were blockedwith 5 % nonfat milk for 2 h and then incubated with
respective primary antibody overnight at 4 °C, followed
by incubation with the appropriate HRP-conjugated
secondary antibody for 2 h at room temperature. Blots
were visualized with an ECL detection kit (Pierce, IL)
and analyzed using Quantity One 1-D Analysis Software
(Bio-Rad, San Francisco, CA).
Real-time PCR assay
Equal amounts of THP-1 cells stimulated by PMA were
treated with the previously collected CM. After 48 h, total
RNA was extracted using TRIzol Reagent (Sigma, St. Louis,
MO). As described before [69], reverse transcription re-
actions and quantitative real-time PCR were performed
using RT-PCR kit (TaKaRa, Shiga, Japan). The primers






CTGTGGCTCTTCTTCGT-3′ [reverse]), CCL22 (5′-A
AACTAATGTCCCTCCCCTCTC-3′ [forward]; 5′-TTT
GGGGCTTCACATTGACC-3′ [reverse]), IL-10 (5′-TG
CCTAACATGCTTCGAGATC-3′ [forward]; 5′-CCAG
GTAACCCTTAAAGTCCTC-3′ [reverse]), and ACTB
(5′-ACTGGGACGACATGGAGAAAATC-3′ [forward];
5′-CTCGCGGTTGGCCTTGG-3′ [reverse]).
Xenograft model of human HCC in nude mice
As described in our previous study [27], male BALB/c
nude mice (5 weeks old) were purchased from the
Shanghai Institute of Materia Medica, Chinese Academy of
Science, and housed under specific pathogen-free condi-
tions. The experimental protocol was approved by the
Shanghai Medical Experimental Animal Care Commission.
Twenty mice were randomized into four groups, and
various cancer cells (6 × 106 cells) in 200 μl of normal
saline were implanted by subcutaneous injection to obtain
subcutaneous tumors. Tumor dimensions were measured
by vernier caliper every 4 days, and the mice were killed
after 4 weeks. After final measurement, the tumors
were placed in 4 % paraformaldehyde solution. The tumor
volume was calculated according to the formula: tumor
volume = (largest diameter × perpendicular height2)/2.
Immunohistochemical assay
Paraffin-embedded tumor tissues from animal Immu-
nohistochemistry was performed on the sections or tis-
sue arrays containing tumor tissues from patients with
HCC who had antibodies against M-CSF (1:100; Abcam,
Cambridge, MA) or CD68 (1:100; Abcam, Cambridge,
MA). The integrated optical density (for M-CSF) or area
(for CD68) of positive staining/total area was quantified
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antibody staining, a uniform setting for all the slides was
applied.
Patients and follow-up
HCC specimens used in the immunohistochemical assay
were obtained from patients who received radical resec-
tion between 1999 and 2003 at the Liver Cancer Institute
and Zhongshan Hospital (Fudan University, Shanghai,
China); these specimens have been described previously
[27, 42]. None of the patients received any preoperative
anticancer treatment. The research was approved by the
research ethics committee of Zhongshan Hospital. A total
of 80 cases were used to examine CD68 expression, and
52 cases were used to examine CD68 expression. The
miR-26a expression data were collected in our previous
study. All the patients were followed up until 2011 with
a median observation time of 60.8 months. This study
was approved by the Zhongshan Hospital Research Ethics
Committee. All patients provided their written informed
consent to participate in this study.
Statistical analysis
Data were analyzed using SPSS 18.0 (SPSS, Inc.). Quantita-
tive variables were analyzed using the unpaired two-tailed
Student’s t test and Spearman correlation test. P < 0.05 was
considered statistically significant.
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